Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Drug design from the cryptic inhibitor envelope.

Chul-Jin Lee1, Xiaofei Liang2, Qinglin Wu1

  • 1Department of Biochemistry, Duke University Medical Center, Durham, North Carolina 27710, USA.

Nature Communications
|February 26, 2016
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physicians and artificial intelligence diverge in evaluating large language models on real clinical cases.

NPJ digital medicine·2026
Same author

Experimental evidence of early-phase transmission of Yersinia pestis by Synopsyllus fonquerniei and Xenopsylla brasiliensis.

PLoS neglected tropical diseases·2026
Same author

Distinct Roles of Transketolase (TktA) and Transaldolase (talB) in Metabolism, Biofilm Formation, and Flea Colonization in <i>Yersinia pestis</i>.

Pathogens (Basel, Switzerland)·2026
Same author

Metabolic adaptation of Yersinia pestis during flea colonization.

The FEBS journal·2026
Same author

Pseudogenization of the cntQ permease confers distinct yersinopine-metal uptake selectivity in Yersinia species.

Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine·2026
Same author

Torque Teno Virus in Bronchoalveolar Lavage Fluid of Hematological Patients and Association With Pathogens.

Journal of medical virology·2026
Same journal

The BRCA1-A complex restricts replication fork reversal-dependent DNA repair in ATM deficient cells.

Nature communications·2026
Same journal

Signaling downstream of tumor-stroma interaction regulates mucinous colorectal adenocarcinoma apicobasal polarity.

Nature communications·2026
Same journal

Click-polymerized polyenamine membranes for efficient lithium extraction.

Nature communications·2026
Same journal

Joint trajectories of brain atrophy, white matter hyperintensities and cognition quantify brain maintenance.

Nature communications·2026
Same journal

Proton shuttling at electrochemical interfaces under alkaline hydrogen evolution.

Nature communications·2026
Same journal

metilene<sup>3</sup>: identifying DMRs across multiple conditions with auto-classification.

Nature communications·2026
See all related articles

Drug design targeting enzyme LpxC (lipid A biosynthesis) can exploit hidden conformational states. This approach yielded potent picomolar antibiotics against Gram-negative bacteria.

Area of Science:

  • Biochemistry
  • Structural Biology
  • Drug Discovery

Background:

  • Conformational dynamics is crucial for enzyme function but underexplored in drug design.
  • LpxC, an enzyme in Gram-negative bacterial lipid A biosynthesis, is a key antibiotic target.

Purpose of the Study:

  • To investigate if LpxC inhibitors access alternative conformational states.
  • To explore exploiting these "hidden" states for novel antibiotic development.

Main Methods:

  • Nuclear magnetic resonance (NMR) spectroscopy to study inhibitor-target interactions.
  • Analysis of inhibitor binding to LpxC in solution.

Main Results:

  • LpxC inhibitors access minor, dynamically accessible conformational states not seen in crystal structures.

Related Experiment Videos

  • These states form a "cryptic inhibitor envelope" accessible to small molecules.
  • Drug design based on this envelope yielded antibiotics with picomolar inhibition constants.

    • Conclusions:

    • Exploiting inhibitor conformational dynamics can lead to highly potent therapeutics.
    • The cryptic inhibitor envelope approach offers a novel strategy for antibiotic development.
    • This principle may be applicable to optimizing other drug leads.